114 results about "Hepatitis b surface antigen" patented technology

The invention relates to the medicine technical field and concretely relates to a mixture formed by two enantiomorphous eremophilane acids separated from murrey ligularia and the officinal salt as well as the medicine combined material. The enantiomorphous eremophilane acid can be used for preparing the medicine curing hepatitis B virus infectious diseases due to the ability of suppressing the antigenic activity on the surface of hepatitis B virus.

The invention relates to the preparation of brominated flavanonollignan and an application in medicines for treating viral hepatitis B, in particular to a B cyclo-dioxane flavanonollignan compound and a preparation method thereof as well as the application of the compound or pharmaceutically acceptable salts thereof in the preparation of medicines for eliminating hepatitis B surface antigens (HBsAg) and hepatitis B e antigens (HBeAg) and medicines for inhibiting HBV DNA replication. The compound has obvious activity of inhibiting HBsAg and HBeAg, and the intensities of the compound for eliminating HBsAg and HBeAg under the concentration of 20 microgram/millimeter are respectively 2.1 times and 1.2 times larger than the corresponding activity of a positive control medicine alpha-interferon; meanwhile, the compound displays high inhibition ratio more than 57% on HBV DNA at the concentration. The results show that the favonolignan or pharmaceutically acceptable salts thereof can be expected to be used for preparing non-nucleoside type medicines for eliminating HBsAg and HBeAg, inhibiting HBV DNA replication and treating HBV infected diseases.

The invention relates to an isoquinoline compound shown as a formula (A) or a stereoisomer, a pharmaceutically acceptable salt, a hydrate, a solvate or a crystal thereof, a medicinal composition thereof and application thereof as antiviral medicines. The isoquinoline compound inhibits hepatitis B DNA activity and hepatitis B surface antigen activity at the same time. The invention particularly relates to application thereof to preparation of medicines for treating and/or preventing hepatitis B, hepatitis B viruses (HBV) thereof and other viral infectious diseases, in particular to treatment and/or prevention of the hepatitis B and the hepatitis B viruses as HBV Surface antigen inhibitor medicines and HBV DNA production inhibitor medicines.

The invention particularly relates to a kit for determining the surface antigen of the hepatitis B virus, and a preparation method thereof, which belongs to the medical field of immunological analysis. The kit comprises (1) a hepatits B virus surface antigen calibration material; (2) an avidin-coated carrier; (3) the polyclonal antibody or monoclonal antibody of a biotinylated hepatitis B virus surface antibody; (4) the polyclonal antibody or monoclonal antibody enzyme-labeled of the surface antibody; and (5) a chemiluminescent primer. Furthermore, the preparation method comprises the following steps of (1) preparing a calibration material from the pure surface antigen; (2) coating the carrier with avidin; (3) performing biotinylation of the polyclonal antibody or monoclonal antibody of the surface antibody; labeling the polyclonal antibody or monoclonal antibody of the surface body with an enzyme; (4) sub-packaging the calibration material and the chemiluminescent primer; and (5) assembling. The kit has the advantages of simpliness, rapidness, sensitiveness, stability and the like.

The subject invention relates to a novel hepatitis B surface antigen mutant and methods of detecting this mutant, and/or antibodies thereto, in patient samples. In particular, the mutant contains a substitution of amino acid threonine for the amino acid alanine at position 123 in the amino acid sequence of the hepatitis B surface antigen (HBsAg) protein.

The invention provides a nanoparticle vaccine preparation containing a recombinant hepatitis B surface antigen. The preparation comprises the following components: a core which is composed of human serum albumin, the recombinant hepatitis B surface antigen and sodium bicarbonate; an encapsulated layer which is a polylactic acid-polyglycolic acid segmented copolymer for encapsulating the core; an external layer which is composed of chitosan or mannan or a mixture thereof for coating. The preparation method comprises the following steps: (1) adding the recombinant hepatitis B surface antigen, the human serum albumin and sodium bicarbonate are added into a phosphate buffered solution containing polyvinyl alcohol to obtain an internal water phase; (2) dissolving the polylactic acid-polyglycolic acid segmented copolymer into an organic solvent for preparing an oil phase, adding the internal water phase obtained in the step (1) into the oil phase, and stirring at a high speed for forming a W/O primary emulsion; (3) adding the W/O primary emulsion into an external water phase solution containing polyvinyl alcohol, stirring at a high speed for forming a W/O/W complex emulsion, stirring at a low speed, carrying out a centrifugal washing, collecting nanoparticles, carrying out a vacuum freeze drying to obtain the finished product nanoparticle vaccine preparation containing the recombinant hepatitis B surface antigen.

The invention relates to a rapid diagnosis kit for pre-S1 antigens of hepatitis B viruses and a method for preparing the same. The rapid diagnosis kit mainly comprises hepatitis B virus pre-S1 antigen detection test paper formed by adhering a sample pad, a conjugate pad, a reaction film and a water absorbing layer to a lining card in sequence, and the test paper is put in a card box, wherein the conjugate pad is prepared by loading anti-HBs polyclonal antibodies on a glass fiber pad, and a detection carrier nitrocellulose film connected with the glass fiber pad is coated with anti-HBs monoclonal antibodies to form a detection line and simultaneously coated with recombined hepatitis B surface antigens to form a quality control line. By using the rapid diagnosis kit, when the sample to be detected contains the pre-S1 antigens and two magenta lines of the detection line and the quality control line are formed, the sample is judged to be positive; and otherwise, only one magenta line is formed, the sample is judged to be negative. The rapid diagnosis kit is used for detecting the pre-S1 antigens of the hepatitis B viruses in human blood serum or blood plasma and has the advantages of easy operation, rapid diagnosis, good specificity and high sensitivity.

Reagents, methods and immunodiagnostic test kits for the accurate detection of hepatitis B virus (HBV) infection are disclosed. The methods and kits employ novel rabbit monoclonal antibodies directed against HBV surface antigens (HBsAg) with mutations in the “a” determinant region of HBsAg.

The invention relates to an immunochromatographic test paper for detecting hepatitis B surface antigens and a preparation method thereof, belonging to the field of a hepatitis B surface antigen detection technique. The immunochromatographic test paper comprises a sample pad, a nitrocellulose membrane and a water absorption pad which are sequentially connected, wherein the sample pad contains a superparamagnetic composite particle labeled anti-HBsAg antibody; the nitrocellulose membrane is coated with a detection line and a quality control line which are mutually separate; the detection line contains an anti-HBsAg coating antibody; and the quality control line contains goat anti-mouse IgG which can be specifically combined with the anti-HBsAg coating antibody. The immunochromatographic test paper has the advantages of high sensitivity and high specificity, is quick and convenient, and can implement objective determination.

The invention provides a yeast cell for expressing hepatitis B virus surface antigen. The yeast cells contain the constitution matter for expressing the hepatitis B virus surface antigen, and the constitution matter contain 5-15 tandem-arranged hepatitis B virus surface antigen expression cassettes. Each expression cassette includes the elements as follows: (a) an initial signal element AOX; (b) hepatitis B virus surface antigen genes and (c) a terminal signal element AOX (TT). The yeast cells are induced by methanol to express the hepatitis B virus surface antigen and form hepatitis B virus surface antigen virus particles with the expression amount being at least 30mg/L fermented solution. The invention also provides the constitution matter, the preparation method thereof, and a preparation method for the yeast cells and hepatitis B virus surface antigen virus particles expressed by the same. The constituted yeast cell with high copy number and high expression can be used for increasing the yield, reducing the cost, and is suitable for the large-scale production of the hepatitis B virus surface antigen vaccine.

The invention relates to a hepatitis B virus multi-epitope fusion protein and a preparation method and application thereof. The fusion protein is obtained by inserting hepatitis B virus multi-epitope fusion peptide (with the sequence shown as SEQIDNo.1) formed by serially connecting HBsAg313-321, HBsAg335-343, Pol150-159, Pol455-463 and Padre epitopes through connecting peptide between amino acidat the 78th position and amino acid at the 79th position of a hepatitis B virus core protein; and the preparation method comprises the following steps of: constructing a hepatitis B virus multi-epitope fusion protein expression plasmid pET28-HBc-HP; performing isopropyl thiogalactoside (IPTG) inducing expression by using an Escherichia coli expression system; and purifying by using affinity chromatography. The fusion protein carries a plurality of supertype epitopes of hepatitis B surface antigen (HBsAg), hepatitis B core antigen (HBcAg) and polymerase, is viral particles, has the advantages of strong immunogenicity, wide applicable range and the like, and can be used for preparing therapeutic hepatitis B vaccines.

The present invention provides a recombinant humanized anti-hepatitis B surface antigen (HBsAg) Fab antibody as human hepatitis B surface antibody and its preparation method. The preparation method includes the following steps: utilizing phage display technique to obtain the gene of a humanized anti-HBsAg Fab fragment, making expression in prokaryotic expression system, on this basis utilizing PCK technique to amplifying the light-heavy chain gene of Fab, constructing it into the methyl alcohol yeast expression vector, using two-step process to convert yeast, constructing Fab engineering bacterium, secreting, expressing and producing Fab antbody fragment. The Fab antibody has strong HBsAG combination activity and antigen specificity, and the expression product of said gene has high application value in clinical therapy of hepatic disease.

The invention discloses a lucid ganoderma-Cordyceps sinensis granule. A preparation method for the granule comprises the following steps: subjecting purely natural lucid ganoderma to reflux extraction with 70 to 90% ethanol, carrying out pressure reduced condensation, settlement with a ZTC clarifying agent and combination of extracts obtained after extraction three times, filtering the combined extract, then carrying out standing for 10 to 25 h and centrifugation, collecting a precipitate, adding distilled water to dissolve the precipitate, boiling the dissolved precipitate, filtering out insoluble substances while the dissolved precipitate is hot, adding ethanol into an obtained filtrate with stirring until alcohol content reaches 80%, carrying out standing to allow a grayish purple precipitate to be precipitated, drying the grayish purple precipitate at a low temperature to obtain a crude lucid ganoderma polysaccharide product, subjecting the crude lucid ganoderma polysaccharide product to repeated washing and precipitation with 50 to 80% ethanol, carrying out continuous elution and dissolution by using distilled water, concentrating an eluate, adding ethanol until alcohol content reaches 70%, carrying out standing to allow a precipitate to be filtered and drying the precipitate at a low temperature so as to obtain lucid ganoderma polysaccharide; and processing a lucid ganoderma extract particle from 50 to 80% of the lucid ganoderma polysaccharide and mixing the particle and Cordyceps sinensis mycelia according to a ratio of 1: 9 so as to prepare the lucid ganoderma-Cordyceps sinensis granule. The lucid ganoderma-Cordyceps sinensis granule provided by the invention has an immunoloregulation function, enables negative conversion of a hepatitis B surface antigen to be realized and has energy invigorating, foundation strengthening, liver and kidney nourishing, blood circulation promoting and blood stasis removing effects.

The invention relates to a magnetic immunochromatographic strip for detection of hepatitis B surface antigens and a preparation method thereof. The strip is prepared through the following steps: pasting a coating film, a magnetic particle pad combined with hepatitis B surface antibodies, a sample pad and an absorbent pad on a bottom board in sequence at intervals of 2mm, and using a transparent plastic seal film to cover the upper layer. The coating film is pre-coated with hepatitis B surface antigen detection lines and quality control lines. The invention introduces the magnetic immunochromatographic technique and the fluorescein isothiocyanate system into the detection of the hepatitis B surface antigens, and has the advantages of simple operation, high sensitivity and good specificity.

The invention provides a hepatitis B surface antigen detection kit. The kit comprises an alkaline phosphatase labeled F (ab') 2HBsAg sheep polyclonal antibody and a magnetic particle-HBsAg antibody. In the kit disclosed by the invention, the antibody directly coats the magnetic particles, so the reaction efficiency is better, and the sensitivity is favorably improved; some non-specific binding occurs at the FC end of the antibody, and the molecular weight of the cut antibody Fab2 is smaller, so the sensitivity is improved.

Disclosed is an isoquinolinone compound as shown in Formula (I) or a stereoisomer, pharmaceutically acceptable salt, solvate or crystal thereof, and a preparation method thereof, and use thereof in the preparation of drugs for treating or preventing viral infectious diseases caused by the hepatitis B virus (HBV) and other viruses, in particular, use thereof in drugs as HBV surface antigen inhibitors and HBV DNA production inhibitors. The compound has a significant activity in inhibiting hepatitis B surface antigen and hepatitis B DNA, and is possible to significantly improve the probability of curing hepatitis B by administration in combination with nucleoside drugs or other drugs in the future, and has good clinical application prospects.

The invention discloses a method for constructing eukaryon Hansenula polymorpha with recombinant hepatitis B virus genes and a method for producing hepatitis B surface antigens, and belongs to the technical field of bioengineering. The method for constructing the eukaryon Hansenula polymorpha includes steps of 1, constructing plasmids pHPZF1.0-ZS with the recombinant hepatitis B virus HBsAg genes; 2, screening the plasmids to obtain the eukaryon Hansenula polymorpha engineering bacteria with the recombinant hepatitis virus HBsAg genes and the highest expression level. The methods have the advantages that HBsAg recombinant proteins can be stably and efficiently expressed in a methanol induction mode by Hansenula polymorpha engineering bacterial strains of the hepatitis B surface antigens which can be obtained by the aid of the methods, and the methods are suitable for producing the HBsAg recombinant proteins on a large scale.

The invention discloses a preparation method of an anti-hepatitis B surface antigen-antibody based on green fluorescent protein luminescence structural domain labeling. The preparation method with a genetic engineering means adopted includes the following steps that a first DNA sequence of a fusion gene GFP-F-Domain-anti-HBsAg is synthesized; amplification is carried out with the first DNA sequence as a template, and a second DNA sequence is obtained; the second DNA sequence is connected to an expression vector pET22b plasmid, and first target clone groups are obtained; the first target clone groups are subjected to inducible expression, and a first bacteria colony is obtained; the first bacteria colony obtained after inducible expression is broken and purified, and the anti-hepatitis B surface antigen-antibody based on green fluorescent protein luminescence structural domain labeling is obtained. By means of the preparation method, the accuracy of quantitative detection of hepatitis B surface antigens is improved.